JNJ-55375515

JNJ-55375515 is an investigational small molecule drug developed by Janssen Research & Development, a subsidiary of Johnson & Johnson. It is being studied as an oral agent and has completed phase 1 clinical trials in healthy volunteers to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics[1][2][4][5]. The precise mechanism of action remains undefined or unknown in public sources; however, it has been described as a modulator of the metabotropic glutamate receptor 2 (mGluR2), suggesting potential activity on central nervous system pathways[1]. The primary indication for development has not been disclosed.